Work

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation

Year: 2010

Type: article

Source: The Pharmacogenomics Journal

DOI: 10.1038/tpj.2010.64

Authors: A M Leventhal, S P David, M Brightman, D Strong, J E McGeary, R A Brown, E E Lloyd-Richardson, M Munafò, G R Uhl, R Niaura

Institutions: University of Southern California, University of Bristol, Stanford Medicine, Stanford University, Brown University, University of Massachusetts Dartmouth, University of Massachusetts Boston, National Institutes of Health, National Institute on Drug Abuse, Truth Initiative

Language: English

Topic: Smoking Behavior and Cessation

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, Economic and Social Research Council, National Heart, Lung, and Blood Institute, National Institute on Drug Abuse, National Cancer Institute

Awards: G1028571699, Exploratory/Developmental Study of Pharmacogenetic Smoking Cessation Therapy, G2887536712, The UK Centre for Tobacco Control Studies, COPING WITH DEPRESSION IN SMOKING CESSATION, Psychobiological /Genetic Determinants-Smoking Cessation, Nicotine Dependence: Phenotype, Endophenotype & Contexts, MATCHING ANTIDEPRESSANT TREATMENT FOR SMOKING CESSATION, Affective and Genetic Correlates of Amphetamine Response, G6482938342, G6639808263, G6963595227, G8904249130

OpenAlex ID: W2010397972

FWCI: 2.641

Cites: 46

Cited by: 37

Related to: 10